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CLINICAL CASE

DECREASING HYPOGLYCEMIA UNAWARENESS IN A PATIENT WITH TYPE 1
DIABETES MELLITUS AFTER CONTINUOUS GLUCOSE MONITORING:
TOOLS FOR SELF-CARE
DISMINUCIÓN DE HIPOGLICEMIA ASINTOMÁTICA EN UNA PACIENTE CON DIABETES MELLITUS TIPO 1
LUEGO DEL MONITOREO CONTINUO DE GLUCOSA: HERRAMIENTAS PARA EL EMPODERAMIENTO.
Sonia Helen Perez-Cavero 1,5,a, Helard Manrique-Hurtado 2,4,a, Julio Leey-Casella3,a

ABSTRACT

CLINICAL CASE

Diabetes mellitus is a public health problem that causes early and late complications. Continuous glucose
monitoring (CGM) has become the main technological tool for real-time glycemic control and has the
potential to prevent complications. However, its use has not spread in low- and middle-income countries.
We present the experience in the management of a patient with type 1 diabetes with hypoglycemia
unawareness in whom the use of real-time CGM achieved both: less hypoglycemic episodes and optimization
of insulin regimen. The bene t of real-time CGM in addition to the use of analog insulins and diabetes
education resulted in better metabolic control. CGM is a useful tool to consider in patients with hypoglycemia
unawareness and to minimize the risk of complications in the future.
Keywords: Diabetes mellitus type 1; Technology; Education; Blood Glucose Self-Monitoring; Hypoglycemia.
(Source: MeSH NLM)

RESUMEN
La diabetes mellitus es un problema de salud que ocasiona complicaciones tempranas y tardías. El monitoreo
continuo de glucosa (MCG) se ha convertido en la principal herramienta tecnológica para el control glicémico
en tiempo real y evitar las potenciales complicaciones. Sin embargo, su uso no se ha extendido en países de
medianos y bajos ingresos. Se presenta la experiencia en el manejo de una paciente adulta con diabetes tipo 1
con hipoglicemias asintomáticas recurrentes en quien el uso del MCG en tiempo real permitió reducir los
episodios de hipoglicemias y optimizar la insulino terapia. La aplicación del MCG sumado al uso de insulinas
análogas y educación en el manejo de la enfermedad resultó en un mejor control metabólico. El MCG,
especialmente incorporando un sistema de alarma, es una herramienta útil a considerar en pacientes con
hipoglicemia frecuente para minimizar el riesgo de complicaciones a futuro.
Palabras claves: Diabetes Mellitus Tipo 1; Tecnología; Automonitorización de la Glucosa sanguínea;
Hipoglucemia. (Fuente: DeCS - Bireme)
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INTRODUCTION

CLINICAL CASE

Type 1 diabetes mellitus (DM1) represents between 5 to
10% of all diabetes cases and is a condition where beta
cells are destroyed by an autoimmune phenomenon.
The prevalence and incidence of DM1 are
approximately 5.6 and 15 cases per 100,000 inhabitants,
respectively, worldwide(1), with the number of new
cases in children and young people during the COVID19 pandemic being alarming(2).
In Peru, the incidence is low, with approximately one
case per 100,000 inhabitants in children under 15 years
of age(3), but it is increasing. Recently, the National
Institute of Child Health in Peru reported a greater
number of new cases per year between 2011 and 2018
(4)
. Patients with DM1 have greater diﬃculty in reaching
glycated hemoglobin (HbA1c) goals and thus be able to
reduce complications. Fear of hypoglycemia and poor
adherence to treatment in these patients greatly aﬀect
good glycemic control. In parallel, hypoglycemia
increases mortality and cardiovascular risk (5).

glucose was measured 1 or 2 times a day, 50-70% of the
time with a value less than 70 mg/dl, several of
the episodes were asymptomatic. She suﬀered from
almost daily episodes of hypoglycemia either day
and/or night, with documented symptoms up to
approximately 35mg/dl of capillary glucose, some of
them were severe nocturnal hypoglycemia that
required the assistance of another family member with
glucose reaching up to 23 mg/dl.
He has a history of an arm fracture due to severe
hypoglycemia with loss of consciousness. His height is
163 cm and weight 49 Kg (BMI 18.4 Kg/m2), body mass
index is usually less than 20 Kg/m2, he used NPH and
Regular insulin with a total daily dose of insulin (TDD) 1
at 1.2 IU/KG (see Table 2). Auxiliary tests showed the
following results: HbA1c 8.1%, C-peptide <0.01 nmol/L,
total cholesterol: 197 mg/dl, high-density lipoprotein
(HDL) 56 mg/dl, low-density lipoprotein (LDL) 138
mg/dl, triglycerides: 65mg/dl, thyroid-stimulating

Self-monitoring is essential for the control of DM1;
however, the cost of ngerstick glucose monitoring and
the discomfort and pain associated with it limits its use.
In developed countries, the use of continuous glucose
monitoring (CGM) has become the main technological
tool for real-time glycemic control. In Peru, there is a
previous report on the use of CGM in an adult (6) and a
retrospective study of 28 patients between children and
adults (7).

hormone (TSH): 1.52mIU/L, creatinine 1.44mg/dl, and
microalbuminuria 1.4mg/L.
Six days after the teleconsultation, a Free Style Libre 2
CGM sensor was placed. Given the high dose of daily
insulin and the high frequency of hypoglycemia, the
change to insulin analogs was made according to
weight: glargine 18 IU/day and lispro 4/7/5 IU before
breakfast, lunch, and dinner, respectively, while

In this report, we describe the case of a patient with
DM1 with poor metabolic control and recurrent
hypoglycemia in whom the use of real-time CGM
reduced hypoglycemic episodes, improved quality of
life, and reached the appropriate dose of insulin.

providing nutritional education and counseling (see
Table 2). Following the manufacturer's instructions, the
sensor was applied to the skin of the outer aspect of the
arm. Likewise, the Libre 2 scanner was provided and he
was instructed to scan the CGM sensor at least every 8

DESCRIPTION OF THE CLINICAL
CASE
A 39-year-old female patient from the northern region
of Peru, with a personal history of two previous
abortions and DM1 since she was 23 years of age, with a
report of an episode of diabetic ketoacidosis currently
undergoing treatment with insulin therapy. On the rst
visit, the patient is evaluated by teleconsultation due to
con nement due to the COVID-19 pandemic. Capillary
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hours during the 14 days that the sensor lasts. The
patient sent daily insulin dose information and photos
of her food. Correction of insulin doses was coordinated
with her and the accuracy of carbohydrate counting
was reinforced. Additionally, during the 2 weeks of CGM
use, the patient made her own minimal adjustments to
the basal and preprandial insulin doses, empowering
her in the education and management of her diabetes.
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At the beginning

at 4 months

BMI (weight/m2)

18.44

18.06

Weight (kg)

49.0

48.0

HbA1C (%)

8.1

7.3

Hemoglobin (g/dl)

-

13.4

Uric acid (mg/dl)

-

3.2

197

162

56

46.6

Cholesterol LDL (mg/dL)

138

104.9

Triglycerides(mg/dL)

65

63.8

1.44

0.94

-

19

1.4

-

C-peptide (nmol/L)

<0.01

-

TSH (mUI/L)

1.52

-

Creatinine(mg/dL)
TGP or Alanine Aminotransferase
(mUI/mL)24-hour microalbuminuria(mg/L)

The report of the rst CGM obtained a time in the range
of 70 to 180 mg/dl in 66% (the hypoglycemia alarm
setting was from 70 mg/dl), an average glucose of 134
mg/dl, a glucose variability 46.2% and 26 low glucose

CLINICAL CASE

Total cholesterol (mg/dL)
Cholesterol HDL (mg/dL)

events with an average duration of 120 minutes (Figure
1). The basal insulin dose was 18 IU/day and preprandial
insulin was nally divided into 2/2/2 IU on average
(Table 2).

Table 2. Daily Insulin Dose and Continuous Glucose Monitor Data.
Before the use of the CGM

First CGM

Second CGM

1,04 - 1.2
UI/Kg/day

0,57 UI/Kg/day

0,62 UI/Kg/day

NPH
25 and 20 UI

Glargine
U-100 18 UI

Glargine
U-100 21 UI

Regular
-/10/- UI

Lispro
2/2-3/2 UI

Lispro
~3/3/3 UI

Daily dose of insulin (IU)

Basal insulin(UI)

Preprandial insulin (UI)

134

137

46,2%

45,6%

6,5%

6,6%

Time in Range 70-180 mg/dl

66%

70%

Time between 54 and 69 mg/dl

12%

8%

Average glucose (mg/dl)
Glucose variability (%Standard deviation/mean)

Glucose Management Indicator (GMI) or estimated HbA1c
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Time below
54 mg/dl

2%

2%

Time above
180mg/dl

14%

13%

Time above
250mg/dl

6%

7%

Low glucose events

26

18

Mean duration of hypoglycemic episode (minutes)

120

117

3120 minutes
52 hours or
3.8 hours/day
0,69 UI/Kg/day

2106 minutes
35.1 hours or
2.5 hours/day
0,58 UI/Kg/day

Glargine
U-100 18 UI
Lispro
5/7/4 UI
0,57 UI/Kg/day
Glargine
U-100 18 UI
Lispro
4/2-4/2 UI

Glargine
U-100 18 UI
Lispro
2-4/2-4/2 UI
0,62 UI/Kg/day
Glargine
U-100 21 UI
Lispro
~3/3/3 UI

Total duration of hypoglycemia in 14 days

Treatment
changes

Before
sensor

daily dose of insulin
(UI)
Basal Insulin UI)
Preprandial insulin (UI)

After
sensor

Daily Insulin Dose(UI)
Basal Insulin (UI)
Preprandial insulin(UI)

At the four-month outpatient follow-up, she showed

range at 70%, a glucose variability of 46.6% and 18 low

better control of self-monitoring of glucose, with

glucose events with an average duration of 117 minutes

capillary glucose measurement four times a day, and

were recorded (See Figure 1). Control laboratory tests

fewer hypoglycemia episodes. It was decided to install

showed the following results: HbA1C: 7.3%, total

another CGM for two weeks, with an alarm setting from

cholesterol 162 mg/dl, HDL 46.4 mg/dl, LDL 104.9

80mg/dl to prevent hypoglycemic episodes earlier. An

mg/dl, triglycerides 63.8 mg/dl, creatinine 0.4 mg/dl,

average glucose value of 137 mg/dl, a target

TGP or Alanine Aminotransferase 19 mIU/mL.
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Statistics and glucose target.

Time in Range

CMG

First
CMG

CLINICAL CASE

At 4
months:
:
Second
CMG

* MCG: FreeStyle Free 2 Continuous Glucose Monitor.

Figure 1. Report of glucose statistics and time in range using Continuous
Glucose Monitor.
The dose at four months of basal insulin with insulin
glargine was 21 IU/day and insulin lispro 3/3/3 IU/day.
The patient reports less hypoglycemia and better
quality of life, in addition to a better understanding of
the eﬀect of the number of carbohydrates, which allows
her to have more control over the disease.

DISCUSSION
Lhypoglycemia causes cognitive impairment and is
associated with mortality in 4-10% of patients with
DM1, and cases have been described of patients dying
during sleep after long periods of asymptomatic
hypoglycemia(9,10). In the present report, our patient
decreased the number of hypoglycemic events
between the rst and second CGM from 24 to 18
episodes, respectively. Although the average duration
was similar (120 minutes versus 117 minutes), the total
time of hypoglycemia in the 14 days that each GCM
lasted decreased from 3120 minutes (3.8 hours per day)
in the rst GCM to 2106 minutes (2.5 hours per day) in
the second GCM. The higher the frequency of
hypoglycemia, the higher the reactive hyperglycemia
due to the fear of a hypoglycemic episode (9). Recently,

international guidelines, in addition to glycosylated
hemoglobin, recommend goals based on the GCS as
the longest time in range, the shortest time in
hypoglycemia and the lowest glycemic variability to
mitigate long-term complications (11).
In the case of our patient, she reported a decrease in
hypoglycemia episodes with the switch to insulin
analogs. This suggests that, with the previous regimen
of NPH and regular with which she had higher daily
insulin doses, the exposure to daily hypoglycemia was
probably even worse. The use of real-time CGM allowed
the patient to better understand the impact of
carbohydrate intake and its relationship to insulin
doses.
The availability of hypoglycemia alarms on the MCG is
especially useful in patients with a history of
asymptomatic hypoglycemia as in our patient. Many of
the episodes of hypoglycemia are nocturnal and the
alarm shortens the time of exposure to hypoglycemia,
as was observed in a pediatric patient who did not react
to hypoglycemia when using a CGM without a
hypoglycemia alert, but did when she switched to a
CGM with alerts that helped reduce the duration of
hypoglycemia (12).
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in Figure 2. The upper panel shows 20 scans (white

corresponding to hypoglycemia, but the glucose level

circles), two of them with hypoglycemia around 3 PM.

remained at about the same level suggesting no

The previous 15 hours there was no hypoglycemia. The

when she developed marked reactive hyperglycemia,

glucose level is seen to rise 20 minutes after

greater than 300 mg/dL for several hours, suggesting

hypoglycemia was detected. The next day the patient
had a 2-hour episode of hypoglycemia between 2:20
and 4:40 AM. She scanned the MCG at 4:30 which
yielded a value of 52 and within minutes her glucose
level began to rise indicating carbohydrate intake.

excessive carbohydrate intake.
Hypoglycemia is known to transiently and sometimes
permanently aﬀect cognitive function (13) , it is possible
that the frequent episodes of hypoglycemia, especially

prolonged episode of hypoglycemia between 1pm and

that of the same day, may have aﬀected the patient's

5:30pm. The patient per formed several scans

decision-making ability, predisposing her to develop

a p p r o x i m a t e l y 1 p e r h o u r, s e v e r a l o f t h e m

more hypoglycemia that same day in the afternoon.

CLINICAL CASE

However, in the afternoon of the same day she had a

* MCG: FreeStyle Free 2 Continuous Glucose Monitor.

Figure 2. Sample of Daily Glucose Level Recordings.
In a previous report, the case of a 29-year-old patient
with long-standing DM1 who used a blinded CGM
(Lizarzaburu) was described. The blinded CGM does not
show the patient the glucose level in real time but at the
end of the period of use (6 to 14 days later), in the
mentioned case, the CGM showed a time in target range
of 17% and persistent hyperglycemia, it is mentioned
that there was lack of adherence to nutritional control
and physical activity; subsequent controls at the third
and fth year showed gradually less hyperglycemia,
better glycemic control (HbA1c) and with little evidence
of hypoglycemia, however, she reached a higher BMI
than at the beginning.
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To our knowledge, the present report is the rst
Peruvian case of improvement of severe hypoglycemia
and decrease in the frequency of asymptomatic
hypoglycemia with the use of CGM in DM1. In addition
to visualizing her glucose level, the patient had a very
close medical and nutritional follow-up, which
enhanced nutritional education and empowerment.
This improvement continued after 4 months of followup when she even increased the time in target range
from 66% during the rst CGM to 70% in the second
CGM, in addition to a clinically signi cant reduction of
1.3 hours of hypoglycemia per day.
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patients with diabetes have empowered their diabetes
treatment thanks to more stable and predictable
insulins in their absorption (analogs) and the GCM
technology that allows an approach to the ideal therapy
of the patient with DM1. In conclusion, the CGM,
especially incorporating an alarm system, is a useful tool
to consider in patients with diabetes and asymptomatic
hypoglycemia as it allows an optimization of the
insulinization schedule therapy, empowerment of the
patient with carbohydrate intake and insulin use, and a
clinically signi cant decrease in the frequency and total
duration of hypoglycemia.

Authorship contributions: SPC contributed to the
conceptualization, data collection, methodology
design, data analysis, writing of the initial draft, critical
review of the article, writing and approval of the nal
version. HMH contributed to the conceptualization,
methodology design, data analysis, managed the
research activities, writing, and approval of the nal
version. JLC contributed to the conceptualization,
design of the methodology, data analysis, managed the
research activities and nancing and provided the
resources for the research (Sensors and scanners were
donated by Dr. Leey), drafting and revision of the nal
version.

Con icts of interest: The authors declare that they
have no con ict of interest.

CLINICAL CASE

In our setting, a pilot study of 28 patients in pediatric
and adult populations showed that the use of the CGM,
although for a short period of time, was bene cial in
either type 1 diabetes (predominantly children) or type
2 diabetes (predominantly adults). In that study, those
who used the Free 14-day MCG system with scanning,
but without a hypoglycemia alarm, there was a
correlation between the number of scans and time in
the range 70-180 mg/dl, while adults who used the
blinded monitor had no behavioral feedback of
carbohydrate intake as the patient was "blind" to the
glucose level (7). 100 years after the discovery of insulin,
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